All News
Industry Abstract Previews #ACR21 - Horizon, Aurinia, AstraZeneca
The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021. Below is a listing of some of their best studies for you to review and look for in the meeting.
Read Article
Rituximab Patients May Benefit from Third COVID-19 Vaccine Dose
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a t
Read Article
JAK-pot Study: Cycling JAK Inhibitors Effective in Difficult-to-Treat RA
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with one Janus kinase inhibitor (JAK inhibitor) can achieve success either cycling to other JAKi medic
Read Article
Ultra-Low Dose Rituximab Controls Disease Activity in RA
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that in one study, the majority of rheumatoid arthritis patients on an ultra-low dose of the drug rituximab maintained low disease activity for up to four years, and rarely needed to switch to other biologic drugs or glucocorticoids to control their disease (Abstract #1443).
Read Article
Management of Immune-Related Adverse Events - ASCO Guideline
The American Society of Clinical Oncology, Inc (ASCO) has updated its guidelines and recommendations for the management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. Below are select statements from this guideline.
Read Article
Pfizer/Lilly Pull Tanezumab Development
Today, Lilly and Pfizer announced their global clinical development of the NGF inhibitor, tanezumab, has been discontinued due to recent negative opinions from the EMA and FDA advisory committee.
Read Article
New Hope for NonAlcoholic Fatty Liver Disease
The current issue of the NEJM has two articles on nonalcoholic fatty liver disease (NAFLD also called NASH - nonalcoholic steatohepatitis), one dealing with the prognoses, outcomes and mortality of NAFLD and another prospective and promising interventional trial in NASH patients.
Read Article
How Should Patients With Autoimmune Diseases Approach COVID Vaccination?
Healthcare is a personal and individualized relationship between a provider and patient. Each patient is treated according to their particular symptoms and personal health characteristics.
Read Article
Increased Preterm Birth Risk in Psoriatic Arthritis Pregnancies
Pregnancy outcomes may be affected by psoriatic arthritis or antirheumatic treatment; registry cohort study shows that preterm birth and cesarean delivery were mostly increased by antirheumatic treatment, especially biologics.
Read Article
RheumNow Podcast – Rheumatologist Smoke-Enders (10.22.2021)
Today I have a few questions: Is tramadol really a weak narcotic? Should we really still be doing placebo-controlled trials? What are we going to do about our patients who are smokers? This and more, in this week's review of the news and journal articles.
Read Article
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Insights
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are among the most severe drug reactions, as they come with substantial mortality and morbidity. A review of European centers dealing with SJS and TEN shows that despite best treatment practices, the 6-week mortality rate was 21%.
Read Article
Is It OK to Continue TNF Inhibitors with COVID-19 Infection?
Registry level data of patients with immune-mediated inflammatory diseases (IMIDs) diagnosed with COVID-19 should continue their TNF inhibitor (TNFi) therapy as such patients were less likely to experience adverse COVID-19 outcomes (compared to other immunomodulatory treatments).
Read Article
NOBILITY: a Trial of Obinutuzumab in Proliferative Lupus Nephritis
B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.
Read Article
TICOSPA - Does Treat to Target Work in Spondyloarthritis?
Tight-control or treat-to-target (T2T) strategy is advocated in several diseases, but the recent TICOSPA trial in axial spondyloarthritis (axSpA) showed that T2T was not superior to usual care (UC).
Read Article
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
